<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28351">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01817816</url>
  </required_header>
  <id_info>
    <org_study_id>CCH-061203</org_study_id>
    <nct_id>NCT01817816</nct_id>
  </id_info>
  <brief_title>Early Injection of Botulinum Toxin on Motor Function and Gait Pattern in Stroke Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhua Christian Hospital</source>
  <oversight_info>
    <authority>Taiwan: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spasticity, muscle weakness, abnormal gait pattern are co-morbidities commonly seen in
      stroke patients. They cause disabled condition of patients in activities of daily life and
      functional performance, and also accidental falls and subsequent fractures.

      This study is to evaluate and compare the effects of different phase injection of Botulinum
      Toxin Type-A at affected limbs on muscle rheological changes, muscle activity, muscle tone,
      functional performance, gait pattern and energy consumption in stroke patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in the muscle tone in upper and lower extremity</measure>
    <time_frame>4 weeks after injection</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>use modified Ashworth Scale to access elbow, wrist, ankle joint muscle tone 0: normal
slight hypertonus, at the end-range 1+: mild hypertonus, catch when limb is moved (&lt;1/2)
moderate hypertonus,, limbs moves easily (&gt;1/2)
passive movement difficult
rigid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the gait pattern as walking</measure>
    <time_frame>4 weeks after intervention</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Stroke</condition>
  <condition>Spasticity</condition>
  <arm_group>
    <arm_group_label>Botox_A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo_A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receiving placebo injection at both aLE &amp; aUE ; receiving Botox-A at both aLE &amp; aUE at 6-month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox_B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo_B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>receiving placebo injection at both aLE &amp; aUE ; receiving Botox-A only at aLE at 6-month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Botox_A</intervention_name>
    <arm_group_label>Botox_A</arm_group_label>
    <arm_group_label>placebo_A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Botox_B</intervention_name>
    <arm_group_label>Botox_B</arm_group_label>
    <arm_group_label>placebo_B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first-ever stroke, with spasticity within 3-months (MAS=2~3)

          -  independent walking 10 meters (with assistive devices)

        Exclusion Criteria:

          -  recurrent stroke, cognition impaired

          -  lower limb fracture

          -  received anti-spasticity injection in the past
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>PengTa Liu</last_name>
    <phone>886-4-7238595</phone>
    <phone_ext>7427</phone_ext>
    <email>105546@cch.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Taiwan</city>
        <state>Changhua</state>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tseng</last_name>
      <phone>886-4-7238595</phone>
      <phone_ext>4077</phone_ext>
    </contact>
    <investigator>
      <last_name>Tasen Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 18, 2013</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhua Christian Hospital</investigator_affiliation>
    <investigator_full_name>Ta-Sen Wei,MD</investigator_full_name>
    <investigator_title>Director, Physical Medical and Rehabilitation, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
